Amgen’s $3.7bn ChemoCentryx Buy May Help Offset Growing Pains

Big Biotech’s Q2 Revenue Was 1% Above Consensus

 
• By Mandy Jackson
  
Amgen logo on phone screen in front of stock prices
Amgen believes it can more rapidly grow ChemoCentryx's Tavneos sales • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip